Intranasal vaccinations with the trans-sialidase antigen plus CpG adjuvant induce mucosal immunity protective against conjunctival Trypanosoma cruzi challenges

Infection and Immunity

Volumn 78, Issue 3, 2010, Pages 1333-1338

  Giddings, O K ^a   Eickhoff, C S ^a   Sullivan, N L ^a   Hoft, D F ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN A; SIALIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHAGAS DISEASE; COMBINATION CHEMOTHERAPY; CONJUNCTIVA; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, PROTOZOAN; CHAGAS DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; GLYCOPROTEINS; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A, SECRETORY; MICE; MICE, INBRED BALB C; NEURAMINIDASE; OLIGODEOXYRIBONUCLEOTIDES; PROTOZOAN VACCINES; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TEARS; TRYPANOSOMA CRUZI;

EID: 77349120954     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00278-09     Document Type: Article

References (18)

1. Abbas, A. K., K. M. Murphy, and A. Sher. 1996. Functional diversity of helper T lymphocytes. Nature 383:787-793.
2. Apt, W., X. Aguilera, A. Arribada, C. Perez, C. Miranda, G. Sanchez, I. Zulantay, P. Cortes, J. Rodriguez, and D. Juri. 1998. Treatment of chronic Chagas' disease with itraconazole and allopurinol. Am. J. Trop. Med. Hyg. 59:133-138.
3. Costa, F., G. Franchin, V. L. Pereira-Chioccola, M. Ribeirao, S. Schenkman, and M. M. Rodrigues. 1998. Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice. Vaccine 16:768-774.
4. Costa, F., V. L. Pereira-Chioccola, M. Ribeirao, S. Schenkman, and M. M. Rodrigues. 1999. Trans-sialidase delivered as a naked DNA vaccine elicits an immunological response similar to a Trypanosoma cruzi infection. Brazilian J. Med. Biol. Res. 32:235-239.
5. Cross, G. A. M., and G. B. Takle. 1993. The surface trans-sialidase family of Trypanosoma cruzi. Annu. Rev. Microbiol. 47:385-411.
6. Fujimura, A. E., S. S. Kinoshita, V. L. Pereira-Chioccola, and M. M. Rodrigues. 2001. DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene. Infect. Immun. 69:5477-5486.
7. Garcia, S., C. O. Ramos, J. F. Senra, F. Vilas-Boas, M. M. Rodrigues, A. C. Campos-de-Carvalho, R. Ribeiro-Dos-Santos, and M. B. Soares. 2005. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob. Agents Chemother. 49:1521-1528.
8. Giddings, O. K., C. S. Eickhoff, T. J. Smith, L. A. Bryant, and D. F. Hoft. 2006. Anatomical route of invasion and protective mucosal immunity in Trypanosoma cruzi conjunctival infection. Infect. Immun. 74:5549-5560.
9. Hoft, D. F., and C. S. Eickhoff. 2002. Type 1 immunity provides optimal protection against both mucosal and systemic Trypanosoma cruzi challenges. Infect. Immun. 70:6715-6725.
10. Hoft, D. F., and C. S. Eickhoff. 2005. Type 1 immunity provides both optimal mucosal and systemic protection against a mucosally invasive, intracellular pathogen. Infect. Immun. 73:4934-4940.
11. 8+ CTL and B cell-mediated cross-priming. J. Immunol. 179:6889-6900.
12. Hoft, D. F., P. L. Farrar, K. Kratz-Owens, and D. Shaffer. 1996. Gastric invasion by Trypanosoma cruzi and induction of protective mucosal immune responses. Infect. Immun. 64:3800-3810.
13. Leguizamon, M. S., O. E. Campetella, G. Russomando, M. Almiron, I. Guillen, S. M. Ganzalez-Cappa, and A. C. C. Frasch. 1994. Antibodies inhibiting Trypanosoma cruzi trans-sialidase activity in sera from human infections. J. Infect. Dis. 170:1570-1574.
14. Neira, I., F. A. Silva, M. Cortez, and N. Yoshida. 2003. Involvement of Trypanosoma cruzi metacyclic trypomastigote surface molecule gp82 in adhesion to gastric mucin and invasion of epithelial cells. Infect. Immun. 71:557-561.
15. Prata, A. 1999. Evolution of the clinical and epidemiological knowledge about Chagas disease 90 years after its discovery. Mem. Inst. Oswaldo Cruz 94(Suppl 1):81-88.
16. Vasconcelos, J. R., M. I. Hiyane, C. R. Marinho, C. Claser, A. M. Machado, R. T. Gazzinelli, O. Bruna-Romero, J. M. Alvarez, S. B. Boscardin, and M. M. Rodrigues. 2004. Protective immunity against Trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase. Hum. Gene Ther. 15:878-886.
17. Viotti, R., C. Vigliano, H. Armenti, and E. Segura. 1994. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am. Heart J. 127:151-162.
18. Viotti, R., C. Vigliano, B. Lococo, G. Bertocchi, M. Petti, M. G. Alvarez, M. Postan, and A. Armenti. 2006. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann. Intern. Med. 144:724-734.